GET THE APP

Dielectrophoretic device for separation of DNA, RNA, exosome biom | 54406
Journal of Chromatography & Separation Techniques

Journal of Chromatography & Separation Techniques
Open Access

ISSN: 2157-7064

+44 1300 500008

Dielectrophoretic device for separation of DNA, RNA, exosome biomarkers and drug delivery nanoparticles from whole blood, plasma and serum


2nd International Conference and Expo on Separation Techniques

September 26-28, 2016 Valencia, Spain

Michael J Heller

University of California San Diego, USA

Posters & Accepted Abstracts: J Chromatogr Sep Tech

Abstract :

New dielectrophoretic (DEP) devices and techniques now allow rapid isolation and detection of circulating cell free (ccf) DNA, ccf-RNA, exosome biomarkers and drug delivery nanoparticles directly from un-diluted blood, plasma and serum samples. DEP is a well-known technique for separations of cells, nanoparticles and biomolecules. However, until recently, DEP was impractical for use with blood, plasma, serum and other high conductance solutions (>0.1 S/m) i.e., considerable sample dilution was required before DEP could be carried out. Using new DEP microarray devices ccf-DNA, ccf-RNA, exosomes and drug delivery nanoparticles can now be isolated in 10-20 minutes directly from small volumes (25-100 ul) of blood, plasma or serum. Circulating cf-DNA isolated from chronic lymphocytic leukemia (CLL) patient blood and plasma samples by DEP were PCR amplified to identify the VHL genotype and then sequenced. Sequencing results for DEP were comparable to two gold standard methods. DEP was used to carry out the isolation of glioblastoma exosomes from 50 �?¼L of human plasma. RT-PCR analysis of ccf-RNA from exosomes showed presence of mRNA (beta-actin) and mRNA for cancer-specific EGFRvIII. Finally, the DEP was used for the recovery of drug delivery nanoparticles from undiluted human plasma samples. DEP was successful in isolating a wide range of drug delivery nanoparticles, including low density nano-liposomes. New DEP technology sets the stage for seamless sample to answer molecular diagnostics and therapy monitoring, which allows a variety of important cancer and other biomarkers and drug delivery nanoparticles to be rapidly isolated directly from whole blood and other clinical samples.

Biography :

Email: mheller@ucsd.edu

Top